Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

<h4>Background</h4> <p>Biomarkers of intestinal inflammation, faecal calprotectin (FC) and C-reactive protein (CRP), have been recommended to monitor patients with Crohn’s disease (CD), but whether their use in treatment decisions improves outcomes remains unknown. In CALM, we com...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Colombel, J, Panaccione, R, Bossuyt, P, Lukas, M, Baert, F, Vanasek, T, Danalioglu, A, Novacek, G, Armuzzi, A, Hébuterne, X, Travis, S, Danese, S, Reinisch, W, Sandborn, W, Rutgeerts, P, Hommes, D, Schreiber, S, Neimark, E, Huang, B, Zhou, Q, Mendez, P, Petersson, J, Wallace, K, Robinson, A, Thakkar, R, D'Haens, G
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Elsevier 2017

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Míreanna comhchosúla